louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06675370: The Glittre Activities of Daily Living Test in Chronic Low Back Pain
Official title: Validity and Reliability of the Glittre Activities of Daily Living Test for Assessing Functional Status in Individuals with Chronic Low Back Pain
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Chronic Low Back Pain
Lead sponsor: Kirsehir Ahi Evran Universitesi
Sponsor class: OTHER
First posted: 2024-11-05
Enrollment: 42
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Individuals with chronic low back pain who are being followed up at the Department of Physical Medicine and Rehabilitation at Kirsehir Ahi Evran University will be included in the study.

Brief summary: The aim of our study is to investigate the validity and reliability of the Glittre activities of daily living test in individuals with chronic low back pain.


Eligibility criteria: Inclusion Criteria:

* Diagnosed with chronic low back pain
* Chronic low back pain for at least the last 3 months
* Being aged 18-65
* Voluntary participation in the study

Exclusion Criteria:

* Having orthopedic or neurological impairments
* History of surgery due to chronic low back pain in the last 6 months
* Being pregnant
* Participating in regular physical activity in the past 3 months

Primary outcomes:
measure: Daily living activities
timeFrame: 20 minutes
measure: Exercise capacity
timeFrame: 10 minutes
Secondary outcomes:
measure: Musle function
timeFrame: 1 minute
measure: Functional mobility
timeFrame: 1 minute
measure: Disability level
timeFrame: 5 minutes
Other outcomes:
Locations:
city: Kirsehir
country: Turkey
facility: Kirsehir Ahi Evran University
Study officials:
affiliation: Kirsehir Ahi Evran University
name: Merve Firat
role: PRINCIPAL_INVESTIGATOR
affiliation: Kirsehir Ahi Evran University
name: Basak Kavalci Kol
role: STUDY_CHAIR
affiliation: Kirsehir Ahi Evran University
name: Figen Tuncay
role: STUDY_CHAIR
References:
Clinical trial NCT05411770: The Relationship Between The Stomatognathic System, Spine Posture And Pelvic Symmetry
Official title: Investigation of The Relationship Between The Stomatognathic System, Spine Posture and Pelvic Symmetry in Adolescence Individuals
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Stomatognathic System
Spine
Pelvis
Posture
Lead sponsor: Sanko University
Sponsor class: OTHER
First posted: 2022-06-09
Enrollment: 91
Sex: ALL
Minimum age (years): 10
Maximum age (years): 18
Standard ages: CHILD
ADULT
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Healthy adolescent individuals aged 10-18 years were included in the study.

Brief summary: This study was planned to examine the relationship between the stomatognathic system, spine posture and pelvis symmetry. 91 healthy adolescence were included in the study. For stomatognathic system, temporomandibular range of motion with millimeter ruler, cervical joint range of motion and craniovertebral angle measurement with goniometer, tragus-wall distance measurement with tape measure, kyphosis and lordosis angle measurement with Baseline Bubble Inclinometer®, trunk rotation angle scoliometer for scoliosis, lower extremity length measurements for pelvis symmetry were made using a tape measure.


Eligibility criteria: Inclusion Criteria:

* No known neurological, rheumatological, musculoskeletal problems
* Has no visual or hearing impairment
* Ability to adapt to the parameters to be applied in the study
* Ability to perform tests to be applied
* Consists of voluntary adolescent individuals whose families gave permission to participate in the study.

Exclusion Criteria:

* Receiving joint sounds in the form of clicks or crepitations from the TMJ during mouth opening and closing or chewing
* Passion and tenderness in the TMJ on palpation
* Having a tumor Having received orthodontic treatment in the last 3 years
* Having a history of head, neck and maxillofacial surgery

Primary outcomes:
measure: Thoracic kyphosis and lumbar lordosis angle assessment
timeFrame: 12 Weeks
measure: Temporomandibular range of motion
timeFrame: 12 Weeks
measure: Measuring the cervical joint range of motion
timeFrame: 12 Weeks
measure: Craniovertebral angle measurement
timeFrame: 12 Weeks
measure: Tragus-to-wall distance measurement
timeFrame: 12 Weeks
measure: Scoliosis angle assessment
timeFrame: 12 Weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Gaziantep
country: Turkey
facility: Sanko University
state: Şehitkamil
Study officials:
affiliation: Sanko University
name: Emine Betül Demirkapi, MSc
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03866642: Two Year Follow up of Cadence Total Ankle Replacement
Official title: Two Year Follow up of Cadence Total Ankle Replacement
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Ankle Arthritis
Lead sponsor: Unity Health Toronto
Sponsor class: OTHER
First posted: 2019-03-07
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with end-stage ankle arthritis requiring surgical intervention.

Brief summary: Over the last decades, total ankle replacement (TAR) emerged as a reliable treatment option in end-stage ankle osteoarthritis (OA) while preserving motion and physiological load. The Cadence™ is a fourth-generation, two-component, fixed-bearing implant with minimal tibial and talar resection. It has been in clinical use since July 2016, the purpose of this study was to compare the clinical outcome and radiological outcomes of total ankle arthroplasty with use of the Cadence™ prosthesis at St. Michael's Hospital.

Detailed description: Over the last decades, total ankle replacement (TAR) emerged as a reliable treatment option in end-stage ankle osteoarthritis (OA) while preserving motion and physiological load. The Cadence™ is a fourth-generation, two-component, fixed-bearing implant with minimal tibial and talar resection. It has been in clinical use since July 2016, the purpose of this study was to compare the clinical outcome and radiological outcomes of total ankle arthroplasty with use of the Cadence™ prosthesis at St. Michael's Hospital.

Eligibility criteria: Inclusion Criteria:

* Ankle arthritis treated with Cadence Total Ankle Replacement system

Exclusion Criteria:

* Under 18 years of age

Primary outcomes:
measure: Implant Survivorship
timeFrame: Two Years
Secondary outcomes:
Other outcomes:
Locations:
city: Toronto
country: Canada
facility: St. Michael's Hospital
state: Ontario
Study officials:
References:
Clinical trial NCT05944042: Hepatic Transplantation Registry
Official title: Hepatic Transplantation Registry
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Identify More Accurate Predictive Models of Transplant Risk to Monitor and Evaluate New and Existing Patient Factors
Lead sponsor: Methodist Health System
Sponsor class: OTHER
First posted: 2023-07-13
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Age ≥18 years Submitted to hepatic transplantation (Current Procedural Terminology® code 47135 Patients will be identified based on ICD-10 procedure codes which are only available post-discharge in the EMR.

Brief summary: The objective is to provide a mechanism to store information regarding the demographic characteristics; pre-, intra-, and post-transplant laboratories; treatment strategies; complications; and outcomes in patients undergoing hepatic transplantation.

Detailed description: This study will be conducted at Methodist Dallas Medical Center and include data from hepatic transplant patients beginning in January 2019 and continuing until statistical significance is achieved. Patients will be identified based on ICD-10 procedure codes which are only available post-discharge in the EMR. Data will be collected once patient is discharged and no additional procedures are necessary. All cases meeting the inclusion criteria are expected to be included in this study

Eligibility criteria: Inclusion Criteria:

* Age ≥18 years Submitted to hepatic transplantation (Current Procedural Terminology® code 47135

Exclusion Criteria:

* Does not meet inclusion criteria specified in 3.1

Primary outcomes:
measure: Need for prospective registry studies to determine patient factors to measure long-term survivial
timeFrame: 2 years
measure: Methods of storing information on demographics of transplant patients
timeFrame: 2 yrs
Secondary outcomes:
measure: Total Number and Description of Study Sites/Total Number of Subjects Projected
timeFrame: 2 yrs
Other outcomes:
Locations:
city: Dallas
country: United States
facility: Methodist Dallas Medical Center
state: Texas
Study officials:
References:
citation: Jadlowiec CC, Taner T. Liver transplantation: Current status and challenges. World J Gastroenterol. 2016 May 14;22(18):4438-45. doi: 10.3748/wjg.v22.i18.4438.
citation: Zimmerman MA, Ghobrial RM, Tong MJ, Hiatt JR, Cameron AM, Hong J, Busuttil RW. Recurrence of hepatocellular carcinoma following liver transplantation: a review of preoperative and postoperative prognostic indicators. Arch Surg. 2008 Feb;143(2):182-8; discussion 188. doi: 10.1001/archsurg.2007.39.
Clinical trial NCT02297542: Immune Response to High-Dose vs. Standard Dose Influenza Vaccine
Official title: Immune Response to High-Dose vs. Standard Dose Influenza Vaccine
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Elderly Immune System
Keywords: Influenza Vaccine
Lead sponsor: Health Sciences North Research Institute
Sponsor class: OTHER
Collaborators: name: UConn Health
First posted: 2014-11-21
Enrollment: 85
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: FACTORIAL
Primary purpose: PREVENTION

Brief summary: This 5-year proposal is a randomized study of split-virus influenza vaccine (SVV) in a high-dose (HD) vs. standard-dose (SD) formulation in each of five influenza seasons to define the key determinants of vaccine-mediated protection against influenza and how these immunologic mediators may be enhanced by vaccination with a newly approved high-dose influenza vaccine in older people


Eligibility criteria: Inclusion Criteria:

1. Written informed consent provided by the participant
2. Age 20-40 years old with no underlying chronic diseases or age ≥65 years old
3. Willing to receive influenza vaccination
4. Older cohort has received their influenza vaccine for the previous influenza season

   -

Exclusion Criteria:

1. Immunosuppressive disorders or medications (including oral prednisone in doses \>10 mg daily)
2. Have not received influenza vaccination in the past or cannot be vaccinated due to previous severe reaction to influenza vaccine, egg, latex, or thimerosol allergies, or refusal of vaccination
3. Participant has received a community available influenza vaccine for the approaching influenza season
4. Females who are pregnant at Visit 1 (a pregnancy test will be administered for all females of child-bearing potential)

   -

Primary outcomes:
measure: Number of Influenza Cases
timeFrame: five years
Secondary outcomes:
Other outcomes:
Locations:
city: Farmington
country: United States
facility: Center on Aging, UConn Health
state: Connecticut
city: Sudbury
country: Canada
facility: Health Sciences North Research Institute
state: Ontario
Study officials:
affiliation: Health Sciences North Research Institute
name: Janet E McElhaney, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: McElhaney JE, Verschoor CP, Haynes L, Pawelec G, Loeb M, Andrew MK, Kuchel GA. Key Determinants of Cell-Mediated Immune Responses: A Randomized Trial of High Dose Vs. Standard Dose Split-Virus Influenza Vaccine in Older Adults. Front Aging. 2021 May;2:649110. doi: 10.3389/fragi.2021.649110. Epub 2021 May 21.
Clinical trial NCT01206842: Social Cognition Training in Schizophrenia
Official title: Social Cognition Training in Schizophrenia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Schizophrenia
Social Cognition
Keywords: functional capacity
training
neurocognition
Lead sponsor: Oslo University Hospital
Sponsor class: OTHER
First posted: 2010-09-22
Enrollment: 48
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: People with schizophrenia show deficits in social cognition, the ability to process information about other people such as identifying their emotional expressions. Social cognition is associated with everyday life functioning and could therefore be an important treatment target. Several social cognitive training programs have been developed during the last years. Results indicate that social cognitive performance can be ameliorated through commonly used intervention techniques. However, it is less clear whether this improvement generalizes to everyday life. The purpose of this study is to investigate if a social cognitive training program (Training in Affect Recognition) improves performance on social cognitive and neuropsychological tests and leads to improved everyday life functioning in persons with schizophrenia. The study also aims at examining if an improvement is present three months after completion of the training intervention.


Eligibility criteria: Inclusion Criteria:

* age 18-55
* diagnosis of schizophrenia or schizoaffective disorder
* IQ \> 69
* sufficient mastery of Norwegian to undergo assessments

Exclusion Criteria:

* history of head trauma
* neurological/medical condition known to interfere with central nervous system
* receiving outpatient care at time of recruitment

Primary outcomes:
measure: Social cognitive tests
timeFrame: Within one week and within three months of completed training
Secondary outcomes:
measure: Functional capacity tests
timeFrame: Within one week and within three months of completed training
measure: Neuropsychological tests
timeFrame: Within one week and within three months of completed training
Other outcomes:
Locations:
city: Oslo
country: Norway
facility: Oslo University Hospital
Study officials:
affiliation: Oslo University Hospital, Psychosis Research Unit
name: Anja Vaskinn, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01139242: Increasing Colorectal Cancer Screening in Urban African American Communities Via Churches
Official title: Increasing CRC Screening in Urban African American Communities Via Churches
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Colorectal Cancer
Keywords: CRC screening status
physical activity level
fruit and vegetable consumption
Early Detection of Cancer
Colorectal Cancer (CRC) screening status
Lead sponsor: University of North Carolina, Chapel Hill
Sponsor class: OTHER
Collaborators: name: Centers for Disease Control and Prevention
First posted: 2010-06-08
Enrollment: 955
Sex: ALL
Minimum age (years): 50
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This is an intervention study to increase colorectal cancer screening and physical activity in members of African-American churches who are 50 years old and older. The control arm receives the Body \& Soul program, a program to increase fruit and vegetable intake. The investigators hypothesize that those receiving the intervention, which includes four tailored newsletters and peer counseling, will be more likely to be screened if not up-to-date, and more likely to increase physical activity if screening was up-to-date at baseline, than controls.


Eligibility criteria: Inclusion Criteria:

* Members of African-American churches who are at least 50 years old.

Exclusion Criteria:

* Non-members of African-American churches; members who are under 50 years of age.

Primary outcomes:
measure: Higher incidence of CRC screening, if needed, among experimental participants.
timeFrame: One year
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: UNC - Chapel Hill
name: Marci K Campbell, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02410642: NAG-excretion During Cardiopulmonary Bypass
Official title: Effects of Cardiopulmonary Bypass on Urinary Secretion of NAG
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Renal Impairment
Keywords: cardiopulmonary bypass
Lead sponsor: Sahlgrenska University Hospital
Sponsor class: OTHER
First posted: 2015-04-07
Enrollment: 65
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: 60 patients scheduled for complex cardiac surgery

Brief summary: NAG is a protein excreted in urine in cases of tubular damage, and is considered a biomarker of kidney injury. Elevated urinary NAG is seen after cardiac surgery, but the clinical significance, pattern of excretion and links to perioperative factors are poorly described. We plan a study of the pattern of NAG-excretion during cardiac surgery with cardiopulmonary bypass, and explore possible associated variables.

Detailed description: The standard biomarker of AKI, serum creatinine, has poor specificity and sensitivity in the early phases of renal injury. Since the therapeutic window is likely to be in the earlier stages before renal injury is manifest, there is a need for novel diagnostic methods. In the recent years, several new biomarkers of kidney injury have been introduced. To date, none has proven outstanding regarding precision in early detection of AKI. NAG (N-acetyl-b-D-glucosaminidase) is a lysosomal enzyme with high molecular weight. Due to its size, NAG does not normally pass the glomerulus apparatus, but urine levels are elevated after tubulus damage. NAG excretion in urine is seen in AKI after cardiac surgery, exposure to nephrotoxic agents and after renal transplantation. However, its role in clinical decision-making is yet to be established.

We aim to study the excretion pattern of urinary NAG during and after cardiac surgery with cardiopulmonary bypass. Association with perioperative variables will be explored.

Eligibility criteria: Inclusion Criteria:

* Expected cardiopulmonary bypass time exceeding 60 minutes
* Elective surgery

Exclusion Criteria:

* End-stage kidney disease with dialysis
* Ongoing treatment with nephrotoxic antibiotic agent

Primary outcomes:
measure: Urinary NAG secretion
timeFrame: 24 hours
Secondary outcomes:
measure: Development of AKI (acute kidney injury) according to AKIN criteria
timeFrame: 72 hours
Other outcomes:
measure: Perioperative factors influencing NAG-secretion
timeFrame: 24 hours
Locations:
city: Gothenburg
country: Sweden
facility: Department of thoracic anesthesia, Sahlgrenska University Hospital
Study officials:
References:
Clinical trial NCT06140342: A Music-Based Mobile App for People Living With Alzheimer's Disease and Related Dementias (ADRD)
Official title: A Music-Based Mobile App to Combat Neuropsychiatric Symptoms in People Living With ADRD
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Dementia
Agitation
Depressive Symptoms
Lead sponsor: Autotune Me LLC
Sponsor class: OTHER
Collaborators: name: University of Pennsylvania
name: National Institute on Aging (NIA)
First posted: 2023-11-20
Enrollment: 20
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Older adults 65+.with dementia who demonstrates symptoms of dementia such as agitation or depressive symptoms.

Caregiver of a person with dementia

Brief summary: The purpose of this pilot is to develop a mobile application that detects physiological measures of individuals with Alzheimer's disease and related dementias and triggers auto-play of personalized songs in a wearable device. The investigators will test the feasibility and acceptability of the app. This app may be an important tool to include in daily caregiving in a home setting by extending established benefits of music therapy for people with Alzheimer's disease and related dementias.


Eligibility criteria: Inclusion Criteria for person with dementia

* A person with ADRD exhibits neuropsychiatric symptoms of dementia such as agitation, restlessness, depressed mood, etc.
* Stability with or without psychotropic or anti-depressant medications
* Ability to hear with or without an assistive device

Inclusion Criteria for Caregivers

* Family or close friend caregiver of persons with dementia
* Must be able to read and write in basic English

Exclusion Criteria for all participants

* Inadequate hearing
* History of psychosis or other mental disorders other than depression
* Presence of substance or alcohol abuse

Primary outcomes:
measure: Usability of mobile app
timeFrame: 2 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Brooklyn
country: United States
facility: Autotune Me, LLC
state: New York
Study officials:
References:
Clinical trial NCT02162342: Quantification of Kinematics and Muscle Activity Patterns of the Upper Extremities of Individuals With Motor Disabilities
Official title: Quantification of Kinematics and Muscle Activity Patterns of the Upper Extremities of Individuals With Motor Disabilities
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Diagnosis and Follow up on Upper Extremity Interventions
Keywords: upper extremity
muscle activity
kinematics
motion capture
Electromyography
Lead sponsor: Hadassah Medical Organization
Sponsor class: OTHER
First posted: 2014-06-12
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Sampling method: PROBABILITY_SAMPLE
Study population: stroke, multiple sclerosis, cerebral palsy, traumatic brain injury, spina bifida, poliomyelitis, neuropathy

Brief summary: The subjet is sitting on a chair and in front of him an adjustable (height) table with a glass of water. 17 passive reflective markers are placed on his upper extremities and torso. The subject is requested to reach the glass (once with the right hand and then with the left hand) and bring it to the mouth and drink. Then the subject put the glass back at the starting position. This is performed twice for each hand. In the second part, the same trial is repeated but muscle activity is recorded with surface electromyography.


Eligibility criteria: Inclusion Criteria:

* motor impairment following stroke, multiple sclerosis, cerebral palsy, traumatic brain injury, spina bifida, poliomyelitis, neuropathy
* Able to understand and sign an informed consent form independently.

Exclusion Criteria:

* Unable to hold or lift a glass
* pregnant women

Primary outcomes:
measure: joint angle
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Jerusalem
country: Israel
facility: Hadassah Medical Organization
Study officials:
References: